MedTrace Logo

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-10-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with Mirabegron will improve urinary urgency control beyond that achieved with pelvic floor exercises alone

Conditions

Interventions

DRUG

Mirabegron

see detailed information in associated Arm Description

DRUG

Placebo

Sugar pill manufactured to mimic Mirabegron 25mg tablet.

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Theodore R. Brown, MD MPH

    lead OTHER

Principal Investigators

  • Theodore R Brown, MD, MPH · EvergreenHealth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2019-04-30
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02086188 on ClinicalTrials.gov